Company “Russian Pharmaceutical Technologies” (Ruspharmtech) has increased the commercial value of its patent profile by receiving an American patent. The document contains information about originality and innovativeness of company’s development - the drug alofanib, which is the first of class allosteric inhibitor of fibroblast growth factor receptor type 2 (FGFR2) intended for cancer treatment.
The Russian company «Ruspharmtech» got a US patent for Alofanib - the first of the class allosteric inhibitor of FGFR2 for cancer treatment.
...
Satisfied Users & 
Approved Press Releases
